Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
July 25, 2014

Recent Stories of Interest

From Drug Benefit News - Express Scripts Holding Co. this month began what some say is the most aggressive approach yet to managing the rising cost of compounded medications by blocking coverage of more than 1,000 ingredients that are potentially driving up spend in this traditional category. But others like Catamaran Corp. (DBN 6/27/14, p. 4), CVS Caremark Corp. and the UnitedHealth Group PBM subsidiary OptumRx have launched initiatives to ensure that clients are not paying for compounded medications that have no additional clinical value over commercially available, FDA-approved medications without implementing sweeping edits. Read more

While PBMs have been giving significant attention to the rising cost of… Read more

Earlier this month, rumors of a possible sale of Humana Inc.’s PBM… Read more

The last of the annual “drug trend reports” released this year by… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

July 24, 2014
FDA Accepts Sandoz’s Biosimilar Filgrastim Application

Sandoz says FDA has accepted its application for biosimilar filgrastim; company is first to file a biologic application under the biosimilar pathway

July 18, 2014
Clone of Shire Agrees to Acquisition by AbbVie

On fifth attempt, Shire finally agrees to be purchased by AbbVie; deal is worth nearly $55 billion and is expected to close in the fourth quarter. Shire will move corporate tax headquarters to Britain

July 15, 2014
Compounding Industry Launches Counterattack on PBMs

Compounding industry launches counterattack on PBMs' efforts to limit compounded meds.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?